Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growing demand for personalized therapy
3.4.1.2. Increased prevalence of life-threatening diseases worldwide
3.4.1.3. Technological advancements in the molecular techniques used for pharmacogenomics-based diagnostics

3.4.2. Restraints

3.4.2.1. Dearth of well-trained and technically skilled professionals
3.4.2.2. Complexities in finding the right gene affecting the drug response

3.4.3. Opportunity

3.4.3.1. Technological advancements in molecular techniques used for pharmacogenomics diagnostic tests
3.4.3.2. Lucrative opportunities in the emerging economies

3.5. Top Player Positioning, 2017

Chapter: 4: GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Next Generation Sequencing

4.2.1. Key market trends and growth opportunities
4.2.2. Market Size and forecast

4.3. Polymerase Chain Reaction

4.3.1. Key market trends and growth opportunities
4.3.2. Market Size and forecast

4.4. Gel electrophoresis

4.4.1. Key market trends and growth opportunities
4.4.2. Market Size and forecast

4.5. Mass Spectrometry

4.5.1. Key market trends and growth opportunities
4.5.2. Market Size and forecast

4.6. Microarray

4.6.1. Key market trends and growth opportunities
4.6.2. Market Size and forecast

4.7. Others

4.7.1. Key market trends and growth opportunities
4.7.2. Market Size and forecast

Chapter: 5: GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cardiovascular disease

5.2.1. Market Size and forecast

5.3. Infectious diseases

5.3.1. Market Size and forecast

5.4. Oncology

5.4.1. Market Size and forecast

5.5. Neurological diseases

5.5.1. Market Size and forecast

5.6. Psychiatry

5.6.1. Market Size and forecast

5.7. Others

5.7.1. Market Size and forecast

Chapter: 6: GLOBAL PHARMACOGENOMICS MARKET BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals and Clinics

6.2.1. Market Size and forecast

6.3. Research Institutions and Academic institutes

6.3.1. Market Size and forecast

6.4. Others

6.4.1. Market Size and forecast

Chapter: 7: PHARMACOGENOMICS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America market size and forecast, by country

7.2.2.1. U.S. market size and forecast, by technology
7.2.2.2. U.S. market size and forecast, by application
7.2.2.3. U.S. market size and forecast, by end user
7.2.2.4. Canada market size and forecast, by technology
7.2.2.5. Canada market size and forecast, by application
7.2.2.6. Canada. market size and forecast, by end user
7.2.2.7. Mexico market size and forecast, by technology
7.2.2.8. Mexico market size and forecast, by application
7.2.2.9. Mexico. market size and forecast, by end user

7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany market size and forecast, by technology
7.3.2.2. Germany market size and forecast, by application
7.3.2.3. Germany. market size and forecast, by end user
7.3.2.4. France market size and forecast, by technology
7.3.2.5. France market size and forecast, by application
7.3.2.6. France. market size and forecast, by end user
7.3.2.7. Spain market size and forecast, by technology
7.3.2.8. Spain market size and forecast, by application
7.3.2.9. Spain. market size and forecast, by end user
7.3.2.10. Italy market size and forecast, by technology
7.3.2.11. Italy market size and forecast, by application
7.3.2.12. Italy. market size and forecast, by end user
7.3.2.13. UK market size and forecast, by technology
7.3.2.14. UK market size and forecast, by application
7.3.2.15. UK. market size and forecast, by end user
7.3.2.16. UK market size and forecast, by technology
7.3.2.17. Rest of Europe market size and forecast, by technology
7.3.2.18. Rest of Europe market size and forecast, by application
7.3.2.19. Rest of Europe. market size and forecast, by end user

7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. China market size and forecast, by technology
7.4.2.2. China market size and forecast, by application
7.4.2.3. China. market size and forecast, by end user
7.4.2.4. Japan market size and forecast, by technology
7.4.2.5. Japan market size and forecast, by application
7.4.2.6. Japan. market size and forecast, by end user
7.4.2.7. India market size and forecast, by technology
7.4.2.8. India market size and forecast, by application
7.4.2.9. India market size and forecast, by end user
7.4.2.10. Rest of Asia-Pacific market size and forecast, by technology
7.4.2.11. Rest of Asia-Pacific market size and forecast, by application
7.4.2.12. Rest of Asia-Pacific. market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Latin America market size and forecast, by technology
7.5.2.2. Latin America market size and forecast, by application
7.5.2.3. Latin America market size and forecast, by end user
7.5.2.4. Middle East market size and forecast, by technology
7.5.2.5. Middle East market size and forecast, by application
7.5.2.6. Middle East. market size and forecast, by end user
7.5.2.7. Africa market size and forecast, by technology
7.5.2.8. Africa market size and forecast, by application
7.5.2.9. Africa market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user

Chapter: 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance

8.2. Admera Health

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio

8.3. Dynamic DNA Laboratories

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio

8.4. Empire Genomics, LLC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio

8.5. F. Hoffmann-La Roche Ltd.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Illumina, Inc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. OneOme, LLC

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product Portfolio

8.8. Myriad Genetics Inc.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio

8.9. OPKO Health, Inc. (GeneDx.)

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance

8.10. Thermo Fisher Scientific, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance